In this task, you are given a passage which has a question and the context. You have to generate an answer to the question based on the information present in the context.
--------
Question: Context: Thromboxane A2 (TXA2) can induce the platelet aggregation and lead to thrombosis. This will cause the low-reflow phenomenon after ischemic stroke and aggravate the damage of brain issues. Therefore, it is potential to develop the drugs inhibiting TXA2 pathway to treat cerebral ischemia.', 'This study aims to prove the protective effect of N2 (4-(2-(1H-imidazol-1-yl) ethoxy)-3-methoxybenzoic acid) on focal cerebral ischemia and reperfusion injury through platelet aggregation inhibition.', 'Middle cerebral artery occlusion/reperfusion (MCAO/R) is used as the animal model. Neurological deficit score, Morris water maze, postural reflex test, Limb-use asymmetry test, infarct volume, and water content were performed to evaluate the protective effect of N2 in MCAO/R rats. 9, 11-dieoxy-11, 9-methanoepoxyprostaglandin F2 (U46619) or adenosine diphosphate (ADP) was used as the inducer of platelet aggregation.\Question: Does n2 extenuate experimental ischemic stroke through platelet aggregation inhibition?

Answer: N2 can improve the motor function, learning and memory ability in MCAO/R rats while reducing the infarct volume. N2 can inhibit TXA2 formation but promote PGI2, and can inhibit platelet aggregation induced by U46619 and ADP. Further, N2 inhibits thrombosis with a minor adverse effect of bleeding than Clopidogrel. In conclusion, N2 can produce the protective effect on MCAO/R brain injury through inhibiting TXA2 formation, platelet aggregation and thrombosis.

Question: Context: Transport across the blood-brain barrier (BBB) is an important mediator of beta-amyloid (A) accumulation in the brain and a contributing factor in the pathogenesis of Alzheimer's disease (AD). One of the receptors responsible for the transport of A in the BBB is the low density lipoprotein receptor-related protein 1 (LRP1). LRP1 is susceptible to proteolytic shedding at the cell surface, which prevents endocytic transport of ligands. Previously, we reported a strong inverse correlation between LRP1 shedding in the brain and A transit across the BBB. Several proteases contribute to the ectodomain shedding of LRP1 including the -secretase, a desintegrin and metalloproteinase domain containing protein 10 (ADAM10).", 'The role of ADAM10 in the shedding of LRP1 and A BBB clearance was assessed through pharmacological inhibition of ADAM10 in an in vitro model of the BBB and through the use of ADAM10 endothelial specific knock-out mice. In addition, an acute treatment paradigm with an ADAM10 inhibitor was also tested in an AD mouse model to assess the effect of ADAM10 inhibition on LRP1 shedding and Abrain accumulation.', 'In the current studies, inhibition of ADAM10 reduced LRP1 shedding in brain endothelial cultures and increased A42 transit across an in vitro model of the BBB. Similarly, transgenic ADAM10 endothelial knockout mice displayed lower LRP1 shedding in the brain and significantly enhanced A clearance across the BBB compared to wild-type animals. Acute treatment with the ADAM10-selective inhibitor GI254023X in an AD mouse model substantially reduced brain LRP1 shedding and increased A40 levels in the plasma, indicating enhanced A transit from the brain to the periphery. Furthermore, both soluble and insoluble A40 and A42 brain levels were decreased following GI254023X treatment, but these effects lacked statistical significance.\Question: Does inhibition of ADAM10 promote the clearance of A across the BBB by reducing LRP1 ectodomain shedding?

Answer: These studies demonstrate a role for ADAM10 in the ectodomain shedding of LRP1 in the brain and the clearance of A across the BBB, which may provide a novel strategy for attenuating A accumulation in the AD brain.

Question: Context: 18-glycyrrhetinic acid (18-GA) has multiple beneficial and therapeutic effects. However, its protective roles on methotrexate (MTX)-induced renal injury are not well defined. In the present study, we investigated the possible protective effects of 18-GA against MTX-induced nephrotoxicity in rats.', '18-GA (50 and 100mg/kg) was administered for 7 days either before or after MTX. The rats were decapitated and kidney and serum samples were collected.', 'MTX-induced renal injury in rats was evidenced by the significant (p<0.001) increase in circulating kidney function markers and tumor necrosis factor alpha (TNF-), as well as the histopathological alterations. MTX-induced rats exhibited significantly increased lipid peroxidation (p<0.05) and nitric oxide (p<0.001) levels, with concomitant marked (p<0.001) decline in the antioxidant defenses. 18-GA, administered either before or after MTX, produced a significant amelioration of circulating kidney function markers, TNF-, kidney lipid peroxidation, nitric oxide, and antioxidant defenses. In addition, 18-GA supplementation significantly up-regulated the mRNA abundance of both nuclear factor-erythroid 2-related factor 2 (Nrf2) and hemoxygenase 1 (HO-1) in the kidney of MTX-induced rats.\Question: Does 18-Glycyrrhetinic acid protect against methotrexate-induced kidney injury by up-regulating the Nrf2/ARE/HO-1 pathway and endogenous antioxidants?

Answer:
These results indicate that 18-GA has a protective effect on MTX-induced nephrotoxicity with possible mechanisms of attenuating oxidative stress and inflammation through up-regulating the Nrf2/ARE signaling. These findings make 18-GA candidate as a potent agent in preventing MTX-induced kidney injury.